FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2320053530> ?p ?o ?g. }

• W2320053530 abstract "The study was aimed at evaluating the efficacy and usability of a dispersible form of perindopril in patients with arterial hypertension (HT) in clinical practice.The study enrolled 52 patients with newly diagnosed or uncontrolled HT of grade 1-2. The baseline assessment consisted of physical examination, instrumental and laboratory tests, including electrocardiography, clinical and biochemical blood tests, measurement of daily albuminuria, and estimation of glomerular filtration rate (GFR). The assessment was repeated at 12 weeks of treatment. The patients were asked to complete questionnaires at the first visit, in order to determine the potential need for administration of dispersible tablets, and at the last visit, to evaluate the convenience of their use. Depending on the baseline blood pressure (BP) and the risk for cardiovascular events, patients were treated with perindopril dispersible form 10 mg/daily in monotherapy, or with combination of perindopril 10 mg/daily in the dispersible form and indapamide retard 1.5 mg/daily. The interim assessments of the treatment efficacy and safety were carried out at 2 and 4 weeks, and the final assessment was performed at 12 weeks from inclusion.The target BP was achieved in 22 (42.3%) patients at 2 weeks, 35 (67.3%) patients at 4 weeks, and 50 (96.2%) patients at 12 weeks of treatment. The reductions in systolic and diastolic BP, assessed by office BP measurements and BP self-control, as well as reduction in heart rate became significant (<0.001) as earlier as after 2 weeks of treatment, and this trend continued up to 12 weeks. In addition, the treatment was associated with by a significant reduction in daily albuminuria, serum creatinine, and increase in GFR. According to the survey data, 71.4% of patients preferred dispersible form of perindopril to the ordinary one, considering it as more convenient, effective and applicable in various everyday situations.In patients with HT, the dispersible form of perindopril in monotherapy and in combination with a diuretic provides a rapid and substantial BP reduction, as well as the achievement of target BP values in the majority of cases. In addition, such a treatment is associated with a significant positive effect on the heart rate, as well as on the renal function. Treatment with a soluble form of perindopril is well tolerated by patients and is estimated by them as a convenient and effective one." @default.
• W2320053530 created "2016-06-24" @default.
• W2320053530 creator A5031109695 @default.
• W2320053530 creator A5054950804 @default.
• W2320053530 date "2016-02-27" @default.
• W2320053530 modified "2023-09-26" @default.
• W2320053530 title "Effectiveness of Dispersible Forms of Perindipril in Patients With Uncontrolled Arterial Hypertension in Clinical Practice" @default.
• W2320053530 doi "https://doi.org/10.18565/cardio.2016.2.19-23" @default.
• W2320053530 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28294744" @default.
• W2320053530 hasPublicationYear "2016" @default.
• W2320053530 type Work @default.
• W2320053530 sameAs 2320053530 @default.
• W2320053530 citedByCount "0" @default.
• W2320053530 crossrefType "journal-article" @default.
• W2320053530 hasAuthorship W2320053530A5031109695 @default.
• W2320053530 hasAuthorship W2320053530A5054950804 @default.
• W2320053530 hasConcept C126322002 @default.
• W2320053530 hasConcept C159641895 @default.
• W2320053530 hasConcept C164705383 @default.
• W2320053530 hasConcept C1862650 @default.
• W2320053530 hasConcept C2776525901 @default.
• W2320053530 hasConcept C2777748223 @default.
• W2320053530 hasConcept C2777953023 @default.
• W2320053530 hasConcept C2779200603 @default.
• W2320053530 hasConcept C2779974597 @default.
• W2320053530 hasConcept C57900726 @default.
• W2320053530 hasConcept C71924100 @default.
• W2320053530 hasConcept C84393581 @default.
• W2320053530 hasConceptScore W2320053530C126322002 @default.
• W2320053530 hasConceptScore W2320053530C159641895 @default.
• W2320053530 hasConceptScore W2320053530C164705383 @default.
• W2320053530 hasConceptScore W2320053530C1862650 @default.
• W2320053530 hasConceptScore W2320053530C2776525901 @default.
• W2320053530 hasConceptScore W2320053530C2777748223 @default.
• W2320053530 hasConceptScore W2320053530C2777953023 @default.
• W2320053530 hasConceptScore W2320053530C2779200603 @default.
• W2320053530 hasConceptScore W2320053530C2779974597 @default.
• W2320053530 hasConceptScore W2320053530C57900726 @default.
• W2320053530 hasConceptScore W2320053530C71924100 @default.
• W2320053530 hasConceptScore W2320053530C84393581 @default.
• W2320053530 hasLocation W23200535301 @default.
• W2320053530 hasLocation W23200535302 @default.
• W2320053530 hasOpenAccess W2320053530 @default.
• W2320053530 hasPrimaryLocation W23200535301 @default.
• W2320053530 hasRelatedWork W1969798464 @default.
• W2320053530 hasRelatedWork W1974262644 @default.
• W2320053530 hasRelatedWork W1986529366 @default.
• W2320053530 hasRelatedWork W2147908827 @default.
• W2320053530 hasRelatedWork W2165722575 @default.
• W2320053530 hasRelatedWork W2317786378 @default.
• W2320053530 hasRelatedWork W2993862412 @default.
• W2320053530 hasRelatedWork W383501651 @default.
• W2320053530 hasRelatedWork W39045554 @default.
• W2320053530 hasRelatedWork W4224210869 @default.
• W2320053530 isParatext "false" @default.
• W2320053530 isRetracted "false" @default.
• W2320053530 magId "2320053530" @default.
• W2320053530 workType "article" @default.